ProJenX spun out of a long-term collaboration between the ALS research nonprofit, Project ALS, and researchers at Columbia University, who have worked together for over twenty years toward a shared goal of developing the first effective treatments, and ultimately a cure, for ALS.Learn More
Prosetin: Changing the Trajectory of ALS
Prosetin is the first brain-penetrant MAP4K inhibitor therapy to enter clinical trials. ProJenX scientific co-founders at Columbia University have shown that prosetin is highly effective across multiple laboratory models of ALS.
ALS in a Dish
Novel, brain-penetrant kinase inhibitors
Developing prosetin for people with ALS is our top priority. At the same time, we are exploring the role of MAP4K inhibition in treating other neurodegenerative disorders that trigger endoplasmic reticulum (ER) stress-mediated degeneration of neurons, and in other debilitating brain diseases in which this pathway play an established biological role.
A Deeply Personal Mission
Project ALS, founded in 1998 by Jenifer, Meredith, and Valerie Estess after Jenifer’s ALS diagnosis at 35, began with a powerful call to arms: I do not find this acceptable. There were no treatments for ALS, and no dedicated research efforts to understand this complex brain disease. Project ALS, with research partners at Columbia and beyond, set out to change this paradigm.
ProJenX, named for Jenifer Estess, was launched in this same spirit. We have come this far guided by scientific rigor, by powerful advocacy, and most of all, by love—and we will not stop until people diagnosed with ALS have access to meaningful treatments.